Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Survival exceeds 90% in transplant for SCD

Publish date:: June 9, 2019

Key clinical point: A prophylactic regimen before bone-marrow transplant (BMT) for sickle cell disease achieved excellent outcomes.

anemMajor finding: Overall one-year survival was 91%.

Study details: A multicenter pilot study of 22 patients between ages 17 and 36 who had BMT.

Disclosures: Dr. Krishnamurti did not disclose any financial relationships.

Citation:

Krishnamurti L et al. FSCDR 2019

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Anemia

Emotions, worse attention linked to pain-related health care use SCD,

Oxidatative stress-related genetic variant tied to stroke risk in sickle cell patients,

Genetic variants may predict stroke in some adult SCD populations,

Severe COVID-19 may lower hemoglobin levels,

Low plasma sodium levels can predict complications in acute painful episodes of SCD,

All Specialties